AUROBAC THERAPEUTICS
BiotechnologyView the employees at
AUROBAC THERAPEUTICS-
Florence Sejourne CEO at Aurobac Therapeutics
-
Top 10%
Esther Duperchy Research Director-
Milton, England, United Kingdom
-
Top 10%
-
Overview
AUROBAC THERAPEUTICS is a biopharmaceutical company created in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to develop the next generation of precision medicines addressing the medical needs associated with the development of antimicrobial resistance and infectious diseases. The company is building a pipeline of drug candidates for hospitalized patients, associated with rapid diagnostics to identify pathogens and their resistance mechanisms. This 40 million euros-funded joint-venture plans to cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization